Invitation - Presentation of Interim Report for January- June 2007
Invitation - Presentation of Interim Report for January- June 2007
Biovitrum, invites media and analysts to a press- and analyst meeting in
Stockholm on Thursday August 23 in conjunction with the disclosure of the
Interim Report for January-June 2007.
The report will be presented by CEO Martin Nicklasson and CFO Göran Arvidson.
Press and analyst meeting in Stockholm:
Time: Thursday, August 23 at 15.00 (CET)
Venue: Grand Hôtel, conference room “Vapensalen”
Coffee will be served.
The report is scheduled for publication at 08.30 (CET) the same day.
Participation:
To participate please register to Lotta Nerblad, e-mail lotta@zoomvision.se or
telephone +46 8 21 10 60.
___________________________________________________________________
Internet broadcast:
A live broadcast from the presentation will be available on the Internet, August
23 at 15. 00 (CET): www.biovitrum.com
Telephone conference call:
You may also participate by telephone.
Dial-in numbers:
S: +46 8 566 363 29
UK: + 44 203 043 24 36
US : +1 866 458 40 87
The slide presentation from the conference will be available on
www.biovitrum.com /investor relations/ presentations.
For more information, please contact:
Biovitrum AB (publ)
Martin Nicklasson, CEO
Phone: +46 8 697 20 00
martin.nicklasson@biovitrum.com
Göran Arvidsson, CFO
Phone: +46 8 697 23 68
goran.arvidson@biovitrum.com
Anna Karin Källén, Vice President, Corporate Communications
Phone: +46 8 697 20 85, Mobile: +46 734 33 20 85
annakarin.kallen@biovitrum.com
About Biovitrum
Biovitrum is one of the largest biopharma companies in Europe. With operations
in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals
for unmet medical needs both for common diseases and conditions that affect
smaller patient populations. Biovitrum has a broad and balanced R&D portfolio
with several projects in clinical and preclinical phases for the treatment of
obesity, diabetes, inflammation and eye and blood diseases as well as a number
of well defined niche indications. Biovitrum develops and produces protein-based
drugs on a contractual basis and markets a range of specialist pharmaceuticals
primarily in the Nordic countries. Biovitrum has revenues of approximately SEK
1.2 billion and 550 employees. Biovitrum is listed on the OMX Nordic Exchange in
Stockholm since September 15, 2006. For more information see www.biovitrum.com/.